Validation of Unani Pharmacopoeial formulations in Zof-e-Masana (Overactive Bladder)
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 300
- 试验地点
- 2
- 主要终点
- Improvements in signs and symptoms of Hypertension
研究概览
简要总结
This study is designed as a multicentric open trial in patients with Zof-e-Masana (Overactive Bladder). Patients will receive the study drugs Majoon Flasfa and Majoon Masik ul baul in a dose of 7 gms each once a day. The total duration of treatment will be 12 weeeks. All the laboratory parameters will be recorded at baseline and at the end of the study. Clinical followups will be done at 1st, 4th, 8th and 12th week.
Composition of MAJOONFALASIFA
1. Maweez Munaqqa 450g
2. Zanjabeel 150g
3. Filfil siyah 150g
4. Filfil Daraz 150g
5. Darchini 150g
6. Amla 150g
7. Post e Balela 150g
8. Sheetraj Hindi 150g
9. Zarawand Madahraj 150g
10. SalabMisri 150g
11. Maghze Chilgoza 150g
12. Bekhe Babuna 150g
13. Maghze Narjeel 150g
14. Tukhme Babuna 75g
15. Asalor Qand e Safaid 7kg
Composition of MAJOONMASIKUL BAUL
1. Aqaqia 15g
2. Gulnar Farsi 15g
3. Habb ul Aas 12g
4. Sandal Safaid 10g
5. Sandal Surkh 10g
6. Adas Surkh 10g
7. Charaita Shireen 10g
8. Tukhm e Hummaz 10g
9. Samagh e Arabi 10g
10. Tabasheer 10g
11. Kundur 5g
12. Julab Q.S
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 18.00 Year(s) 至 55.00 Year(s)（—）
入选标准
- •1.Age- more than 18 yrs and upto 65 yrs 2.Gender- both 3.History of the following symptoms for more than six months •Urgency of urine •Incontinence •Dysuria.
排除标准
- •Patients with Bladder calculus 2.Patients withUrinary tract infections 3.Patients with Benign Prostrate Hypertrophy 4.Patients with Uterine prolapse 5.Patients with Rectocele/cystocele 6.Patients with Cystitis 7.Patients with Diabetes Mellitus 8.Patients with Hypertension 9.Pregnant and lactating females 10.Neoplasm 11.Patients with Hepatic/Cardiac diseases 12.Medications (anticholinergic, antidepressant, psychotropic, or alpha-blocker) 13.Patients with History of any Spinal cord injury.
结局指标
主要结局
Improvements in signs and symptoms of Hypertension
时间窗: 12WEEKS
次要结局
- Hematological and biochemical assessments for safety